UNIGE document Scientific Article
previous document  unige:112289  next document
add to browser collection
Title

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

Authors
Mattsson, Niklas
Lönneborg, Anders
Blennow, Kaj
Hansson, Oskar
Published in Neurobiology of Aging. 2017, vol. 52, p. 196-213
Abstract Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers. Phase 3 (utility in MCI) is partially achieved. In cohorts with long follow-up time, CSF Aβ42, total tau, and phosphorylated tau have high diagnostic accuracy for MCI due to AD. Phase 4 (performance in real world) is ongoing, and phase 5 studies (quantify impact and costs) are to come. Our results highlight priorities to pursue and to enable the proper use of CSF biomarkers in the clinic. Priorities are to reduce measurement variability by introduction of fully automated assay systems; to increase diagnostic specificity toward non-AD neurocognitive diseases at the MCI stage; and to clarify the role of CSF biomarkers versus other biomarker modalities in clinical practice and in design of clinical trials. These efforts are currently ongoing.
Keywords Alzheimer Disease/diagnosisAmyloid beta-Peptides/cerebrospinal fluidBiomarkers/cerebrospinal fluidCognitive Dysfunction/diagnosisDementia/diagnosisEarly DiagnosisHumansNeurocognitive Disorders/diagnosisPeptide Fragments/cerebrospinal fluidReproducibility of ResultsTau Proteins/cerebrospinal fluid
Identifiers
PMID: 28317649
Full text
Article (Published version) (849 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Troubles de mémoire et maladie d'Alzeimer (935)
Citation
(ISO format)
MATTSSON, Niklas et al. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. In: Neurobiology of Aging, 2017, vol. 52, p. 196-213. https://archive-ouverte.unige.ch/unige:112289

19 hits

0 download

Update

Deposited on : 2018-12-14

Export document
Format :
Citation style :